Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Goodrich

Showing results (111-120 of 113) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 113 results.
Diabetes Care|July 8, 2021
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58Ofri Mosenzon, Stephen D Wiviott, Hiddo J L Heerspink, et al.
Diabetes Care|August 23, 2022
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 TrialOfri Mosenzon, Itamar Raz, Stephen D Wiviott, et al.
The New England Journal of Medicine|November 10, 2025
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis RiskNicholas A Marston, Brian A Bergmark, Veronica J Alexander, et al.
Pageof 12

Showing results (111-120 of 113) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 113 results.
Diabetes Care|July 8, 2021
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58Ofri Mosenzon, Stephen D Wiviott, Hiddo J L Heerspink, et al.
Diabetes Care|August 23, 2022
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 TrialOfri Mosenzon, Itamar Raz, Stephen D Wiviott, et al.
The New England Journal of Medicine|November 10, 2025
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis RiskNicholas A Marston, Brian A Bergmark, Veronica J Alexander, et al.
Pageof 12